Tune in now for a cell therapy panel with CEO Pascal Touchon at Cowen Inc.’s 44th Annual Healthcare Conference. A link to the live webcast can be found in the investor section of our website: lnkd.in/gFWidVC7
We are excited to announce that Atara’s Investigational New Drug application for ATA3219, our investigational, allogeneic, anti-CD19 #CAR#Tcell therapy, has received FDA clearance in systemic lupus erythematosus (#SLE) with #lupusnephritis. Read more: bit.ly/3UTAZK0
It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic#CART programs for hematological malignancies and autoimmune diseases at #JPM24. bit.ly/3vxNksE